U. Arnim

发表

Peripheral blood eosinophils and other non‐invasive biomarkers can monitor treatment response in eosinophilic oesophagitis

M. Vieth, A. Straumann, M. Bajbouj, 2015, Alimentary pharmacology & therapeutics.

STW 5, a Phytopharmacon for Patients With Functional Dyspepsia: Results of a Multicenter, Placebo-Controlled Double-Blind Study

P. Malfertheiner, U. Arnim, U. Peitz, 2007, The American Journal of Gastroenterology.

Validation of the German Inflammatory Bowel Disease Fatigue (IBD-F) Questionnaire

A. Canbay, C. Büning, N. Teich, 2021, Zeitschrift für Gastroenterologie.

Ef ﬁ cacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial

M. Vieth, A. Bredenoord, A. Schoepfer, 2019 .

Contents Vol. 77, 2008

P. Malfertheiner, D. Chang, C. Prinz, 2008, Digestion.

Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting

P. Malfertheiner, A. Leodolter, U. Arnim, 1999, American Journal of Gastroenterology.

Faecal Calprotectin Useful for Clinical Differentiation of Microscopic Colitis and Irritable Bowel Syndrome

P. Malfertheiner, U. Arnim, T. Wex, 2011 .

Eosinophilic esophagitis: Comparison of clinical, endoscopic and histological scoring systems

P. Czapiewski, U. Arnim, A. Link, 2021, Zeitschrift für Gastroenterologie.

[Eosinophilic Esophagitis Update: New Guidelines of the European Study Group EUREOS].

M. Storr, C. Schlag, S. Miehlke, 2018, Zeitschrift für Gastroenterologie - German Journal of Gastroenterology.

951a – Budesonide Orodispersible Tablets are Highly Effective to Maintain Clinico-Histological Remission in Adult Patients with Eosinophilic Esophagitis: Results from the 48-Weeks, Double-Blind, Placebo-Controlled, Pivotal Eos-2 Trial

M. Vieth, A. Bredenoord, A. Schoepfer, 2019, Gastroenterology.

Mo1869 Inverse Correlation of H. pylori and Eosinophilic Esophagitis

P. Malfertheiner, S. Miehlke, U. Arnim, 2014 .

SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease.

N. Teich, A. Stallmach, U. Arnim, 2022, Zeitschrift fur Gastroenterologie.

[Gastroparesis. Definition, diagnostics, and therapy].

U. Arnim, 2015 .

Whipple’s Disease – delay of diagnosis by immunosuppressive therapy; a case-series report

U. Arnim, J. Weigt, A. Canbay, 2022, Zeitschrift für Gastroenterologie.

Ligandrol-induzierte toxische Hepatopathie – ein Fallbericht

U. Arnim, D. Jechorek, V. Keitel-Anselmino, 2022, Zeitschrift für Gastroenterologie.

Validation of Two Calprotectin Rapid Tests in Daily Routine.

P. Malfertheiner, U. Arnim, T. Wex, 2016, Clinical laboratory.

Clinical symptom tool that raises the index of suspicion for eosinophilic oesophagitis in adults and drives earlier biopsy for definitive diagnosis

P. Malfertheiner, S. Miehlke, U. Arnim, 2017, Alimentary pharmacology & therapeutics.

Budesonide Orodispersible Tablets are Highly Effective for Treatment of Active Eosinophilic Esophagitis: Results from a Randomized, Double-Blind, Placebo-Controlled, Pivotal Multicenter Trial (EOS-1)

M. Vieth, A. Bredenoord, A. Schoepfer, 2017 .

Capsule Endoscopy (CE) Increases the Diagnostic Yield of Double Balloon Enteroscopy (DBE) in Patients Being Investigated for Obscure Gastrointestinal Bleeding (OGIB)

P. Malfertheiner, K. Mönkemüller, L. Fry, 2009 .

Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis

P. Malfertheiner, S. Miehlke, U. Arnim, 2016, Alimentary pharmacology & therapeutics.

Eosinophile Ösophagitis (EoE)

U. Arnim, 2021 .

Whipple’s Disease – delay of diagnosis by immunosuppressive therapy; a case-series report

U. Arnim, J. Weigt, A. Canbay, 2022, Zeitschrift für Gastroenterologie.

High rate of post‐therapeutic resistance after failure of macrolide–nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second‐line therapies in a randomized study

P. Malfertheiner, M. Stolte, A. Leodolter, 2002, Alimentary pharmacology & therapeutics.